In one paragraphArticle in Nature aging, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from itWhat it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
5 · Who and what moneyAuthors and funding
27 authors.
Elisabet A FrickIcelandic Heart Association, Kopavogur, Iceland.
Amanda CanoResearch Center and Memory Clinic. Ace Alzheimer Center Barcelona - Universitat Internacional de Catalunya, Barcelona, Barcelona, Spain.
Sergi ValeroResearch Center and Memory Clinic. Ace Alzheimer Center Barcelona - Universitat Internacional de Catalunya, Barcelona, Barcelona, Spain.
Alexander GudjonssonIcelandic Heart Association, Kopavogur, Iceland.
Nancy FinkelNovartis, Cambridge, MA, USA.
Funding
Supplement to AMP-AD Brain Proteomic Network Enhancement, Validation and Translation into CSF BiomarkersU01AG061357 · NIA · EMORY UNIVERSITY · PI LEVEY, ALLAN I, SEYFRIED, NICHOLAS THOMAS · 2018 to 2022
$9.1MSerum proteome analysis of Alzheimer´s disease in a population-based longitudinal cohort study - the AGES Reykjavik studyR01AG065596 · NIA · ICELANDIC HEART ASSOCIATION · PI Valborg Gudmundsdottir · 2021 to 2026
$2.6MBrain Proteomic Network Analysis to Elucidate Mechanisms and Biomarkers for Alzheimer's DiseaseK08AG068604 · NIA · EMORY UNIVERSITY · PI JOHNSON, ERIK C.B. · 2020 to 2024
$762kAGES STUDY-THE REYKJAVIK STUDY OF HEALTHY AGING FOR THE NEW MILLENNIUM-26012100N01AG012100 · NIA · ICELANDIC HEART ASSOCIATION · 2002 to 2004
–Agentschap Innoveren en Ondernemen (Flanders Innovation & Entrepreneurship) Nº PR067/21Icelandic Centre for Research (Rannsóknamiðstöð Íslands) 206692-051Innovative Medicines Initiative (IMI) 115975Innovative Medicines Initiative (IMI) 115985Ministry of Economy and Competitiveness | Instituto de Salud Carlos III (Institute of Health Carlos III) Sara Borrell (CD22/00125)NIA NIH HHS R01 AG065596NIDA NIH HHS HHSN271201200022CU.S. Department of Health & Human Services | NIH | National Institute on Aging (U.S. National Institute on Aging) 1K08AG068604U.S. Department of Health & Human Services | NIH | National Institute on Aging (U.S. National Institute on Aging) 1R01AG065596U.S. Department of Health & Human Services | NIH | National Institute on Aging (U.S. National Institute on Aging) N01-AG-12100U.S. Department of Health & Human Services | NIH | National Institute on Aging (U.S. National Institute on Aging) U01AG061357
6 · The paper itselfAbstract
PubMed holds no abstract for this paper.
Identifiers
PMID39285016
PMCPMC11485289
What Socratic holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390